Pacira BioSciences, Inc. (PCRX)
Automate Your Wheel Strategy on PCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including PCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCRX
- Rev/Share 15.1869
- Book/Share 17.2564
- PB 1.4963
- Debt/Equity 0.797
- CurrentRatio 2.4146
- ROIC -0.0841
- MktCap 1195587354.0
- FreeCF/Share 3.4446
- PFCF 7.5006
- PE -11.5189
- Debt/Assets 0.4011
- DivYield 0
- ROE -0.1294
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PCRX | Truist | Sell | Hold | $8 | $25 | Jan. 30, 2025 |
News
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - PCRX
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=133045&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc.
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Read More
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024.
Read More
Investors who lost money on Pacira BioSciences, Inc. (PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132891&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW ORLEANS, LA / ACCESS Newswire / February 27, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS:PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the "Class Period").
Read More
Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Gregory Renza - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Operator Good day, and thank you for standing by.
Read More
Pacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 – PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132879&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132819&wire=1 or contact Joseph E. Levi, Esq.
Read More
PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.
Read More
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Advances Pacira's “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with disease-modifying potential for prevalent musculoskeletal diseases with significant unmet needs --
Read More
PCRX Deadline: PCRX Investors with Losses in Excess of $100K Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132758&wire=1 or contact Joseph E. Levi, Esq.
Read More
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Read More
Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132745&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132568&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit – PCRX
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Raymond James 46th Annual Institutional Investors Conference on Wednesday, March 5th at 10:25AM ET.
Read More
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Investors who lost money on Pacira BioSciences, Inc. (PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132272&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132245&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Pacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132191&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Pacira BioSciences, Inc. (PCRX)
- IPO Date 2011-02-03
- Website https://www.pacira.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Frank D. Lee
- Employees 788